Banyu Pharmaceutical Co. Ltd

Msd K.k.

Merck Sharp + Dohme Corp.

Akira Naya

Norikazu Otake

Yuji Haga

Akio Kanatani

Toshifumi Kimura

Yufu Sagara

Toshihiro Sakamoto

Yoshio Ogino

Shigeru Tokita

Norikazu Ohtake

Makoto Jitsuoka

Kazuhito Noguchi

Takuya Suga

Ryo Yoshimoto

Tomoshige Numazawa

Toru Fujikawa

Minaho Uchiyama

Yasuhiro Goto

Mark E Layton

Philip E Sanderson

Yoshikazu Iwasawa

Jiabing Wang

Hidetomo Furuyama

Nobuhiko Kawanishi

Takeru Yamakawa

Takashi Mita

Kenji Matsuda

Kevin J Rodzinak

Kenji Ohwaki

Sayaka Mizutani

Yu Onozaki

Toshihiko Saeki

Yufu Owada

The compounds of Formula D are of the class of triazolo-pyrido-pyrazines which are inhibitors of AKT useful for the treatment of cancer 

Substituted [1,2,4]triazolo[4',3&#x2032;:1,6]pyrido[2,3-b]pyrazines of the formula D

Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.

Heteroaryloxy nitrogenous saturated heterocyclic derivative

A compound represented by the formula (I) is contained as an active ingredient: wherein Rand Rindependently represent a hydrogen atom, a lower alkyl group or the like, or Rtogether with a nitrogen atom to which L, Zand Rare attached may form an aliphatic nitrogenated heterocyclic group and Rand Rtogether with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents &#x2014;CH&#x2014;O&#x2014;, &#x2014;CH&#x2550;CH&#x2014; or the like; Zrepresents a single bond, a Calkylene group or the like; Zrepresents a single bond or a Calkylene group; L represents a methylene group, a Ccycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.

Phenylpyridone derivative

The invention provides pyridone derivatives represented by a general formula (I) 

Pyridone derivative

Compound of the formula: (I) [wherein each of X, Xand Xindependently represents N or CH, W represents the formula (II):(II) or the formula (III):(III) and Y represents a group of the formula (IV):(IV)], or a pharmacologically acceptable salt thereof. This compound exhibits histamine receptor H3 antagonist or inverse agonist activity and is useful of the treatment and/or prevention of obesity, diabetes, hormonal secretion abnormality, sleep, disorder, etc. 

This invention relates to compounds which are represented by the general formula [I] [in which A stands for a group of the following formula [a] or [b]  The compounds of the invention exhibit selective antagonism to muscarinic Mreceptors, and therefore are useful as safe and effective agents showing little side effect, for treating diseases of the respiratory, urinary and digestive systems.

Amide derivatives

This invention relates to benzimidazolone derivatives, represented by compounds of a general formula [I]  The benzimidazolone derivatives of the invention exhibit antagonism to muscarinic acetylcholine receptors, and are useful as treating agent and/or prophylactic of Parkinson's disease, drug-induced parkinsonism, dystonia, akinesia, pancreatitis, bilestone/cholecystitis, biliary dyskinesia, achalasia, pain, itch, cholinergic urticaria, irritable bowel syndrome, vomiting, nausea, dizziness, Meniere's disease, motion sickness and urinary disturbance.

Benzimidazolone derivatives

Chemokine receptor antagonists

Growing community of inventors

Tsukuba, Japan

Akira Naya